These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21641842)

  • 1. Remission of Cushing's disease with growth hormone replacement.
    Öztürk M; Atmaca M
    Growth Horm IGF Res; 2011 Aug; 21(4):238-41. PubMed ID: 21641842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early post-operative ACTH and cortisol as predictors of remission in Cushing's disease.
    Acebes JJ; Martino J; Masuet C; Montanya E; Soler J
    Acta Neurochir (Wien); 2007; 149(5):471-7; discussion 477-9. PubMed ID: 17406780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease.
    Patil CG; Veeravagu A; Prevedello DM; Katznelson L; Vance ML; Laws ER
    Neurosurgery; 2008 Aug; 63(2):266-70; discussion 270-1. PubMed ID: 18797356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
    Johannsson G; Sunnerhagen KS; Svensson J
    Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.
    Pecori Giraldi F; Scaroni C; Arvat E; Martin M; Giordano R; Albiger N; Leao AA; Picu A; Mantero F; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):219-24. PubMed ID: 16430724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypopituitarism in Cushing's disease.
    Cavagnini F; Scacchi M; Pecori Giraldi F
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):44-7. PubMed ID: 19020385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.
    Atkinson AB; Kennedy A; Wiggam MI; McCance DR; Sheridan B
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):549-59. PubMed ID: 16268808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease.
    Boguszewski CL
    Pituitary; 2022 Oct; 25(5):760-763. PubMed ID: 35552989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late diagnosis of Cushing's disease in a child: what lessons can be learned?
    Gust DA; Gordon TP
    J Pediatr Endocrinol Metab; 2013; 26(7-8):753-6. PubMed ID: 23612592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-center experience with pediatric Cushing's disease.
    Kanter AS; Diallo AO; Jane JA; Sheehan JP; Asthagiri AR; Oskouian RJ; Okonkwo DO; Sansur CA; Vance ML; Rogol AD; Laws ER
    J Neurosurg; 2005 Nov; 103(5 Suppl):413-20. PubMed ID: 16302612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.
    Estrada J; Boronat M; Mielgo M; Magallón R; Millan I; Díez S; Lucas T; Barceló B
    N Engl J Med; 1997 Jan; 336(3):172-7. PubMed ID: 8988897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing's disease (CD).
    Wagenmakers MA; Netea-Maier RT; van Lindert EJ; Timmers HJ; Grotenhuis JA; Hermus AR
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):274-80. PubMed ID: 18616702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Cushing's disease with ketoconazole].
    Méndez Pérez P; Barrio Castellanos R; Núñez Estévez M; Pérez Rodríguez C; Hernández Doménech R
    An Pediatr (Barc); 2009 Apr; 70(4):366-9. PubMed ID: 19282258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary radiotherapy for Cushing's disease.
    Losa M; Picozzi P; Redaelli MG; Laurenzi A; Mortini P
    Neuroendocrinology; 2010; 92 Suppl 1():107-10. PubMed ID: 20829629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short stature due to growth hormone deficiency associated with Cushing's disease and ulcerative colitis.
    Kotake M; Nakai A; Mokuno T; Oda N; Sawai Y; Itoh Y; Shimazaki K; Kato R; Hayakawa N; Uchikawa A; Oiso Y; Hirooka Y; Mitsuma T; Itoh M; Nagasaka A
    Horm Metab Res; 1996 Oct; 28(10):565-9. PubMed ID: 8934218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steven Johnson syndrome in a patient with Cushing's disease.
    Mustafa N; Periyasamy P; Kamaruddin N
    Med J Malaysia; 2009 Sep; 64(3):238-9. PubMed ID: 20527277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of postoperative ACTH levels as a marker for successful transsphenoidal microsurgery in Cushing's disease.
    Flitsch J; Knappe UJ; Lüdecke DK
    Zentralbl Neurochir; 2003; 64(1):6-11. PubMed ID: 12582940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.